相关实验视频

Updated: Sep 10, 2025

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Orthotopic Implantation and Peripheral Immune Cell Monitoring in the II-45 Syngeneic Rat Mesothelioma Model

Published on: October 2, 2015

在接受免疫治疗的多叶膜间皮瘤患者的预后免疫炎症和转录基因特征

Giulia Mazzaschi^1,2, Roberto Rosati¹, Simona D'Agnelli²

¹Department of Medicine and Surgery, University of Parma, Parma, Italy.

|August 20, 2025

概括

瘤微环境和血液中的生物标志物可以预测晚期多叶膜间皮瘤的免疫治疗反应. 较高的CD4+T细胞和较低的单细胞与更好的存活率相关,而ULBP2则表明预后不佳.

科学领域:

癌症学
免疫学
翻译研究

背景情况:

晚期的肺间皮瘤 (PM) 的治疗选择有限.
免疫治疗 (IT) 是有前途的,但预测疗效至关重要.
了解瘤免疫微环境 (TIME) 和全身炎症是关键.

研究的目的:

确定晚期细菌免疫疗法 (IT) 疗效的预后生物标志物.
使用一种结合 TIME,免疫炎症标志物和转录学的多层次方法.
为了将这些标记与临床结果相关联,例如总生存率 (OS) 和无进展生存率 (PFS).

主要方法:

用尼沃卢马布加上伊皮利穆马布治疗的17名晚期PM患者的预期招募.
使用流细胞计,ELISA,免疫组织化学和纳米链基因表达的基因血液和瘤样本的分析.
评估免疫子集,功能标记物 (Granzyme B,Ki67),细胞因子,TIL,PD-L1和转录组特征.

主要成果:

较高的基线CD4+Granzyme B+T细胞和较低的CD14+单细胞与改善的生存状况,PFS和治疗时间失败 (TTF) 相关.
增多的CD8+ Ki67+ T细胞也预测了更好的PFS和TTF.
较低的IL-2水平与较长的生存期相关,而较高的内CD4+TIL和CD4/CD8比率在长期存活者中被观察到. ULBP2基因表达预测预后不佳.

结论:

综合免疫和转录基因分析成功地确定了IT对PM有益的生物标志物.
特定的免疫细胞群和基因表达特征可以指导治疗决策.
这种多层次的方法为高级瘤患者提供了个性化免疫治疗策略的可能性.

关键词:

CD4+ T 细胞免疫疗法胸腔间皮瘤生物标志物大酶B 周围血液免疫类型测定转录组学瘤免疫微环境

更多相关视频

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

相关概念视频

Pleural Disorders: Types and Brief Description

Pleural Disorders: Types and Brief Description

The pleura is a vital part of the respiratory system. It's a double-layered membrane surrounding the lungs and lining the chest cavity. The two layers of the pleura are:

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.